cris.boxmetadata.label.title
Covid-19 associated rhino-orbital mucormycosis complicated by gangrenous and bone necrosis—a case report from honduras
cris.boxmetadata.label.dateissued
01 browse.startsWith.months.august 2021
cris.boxmetadata.label.accesslevel
open access
cris.boxmetadata.label.resourcetype
journal article
cris.boxmetadata.label.authors
Palou E.Y.
Ramos M.A.
Cherenfant E.
Duarte A.
Fuentes-Barahona I.C.
Zambrano L.I.
Muñoz-Lara F.
Montoya-Ramirez S.A.
Cardona-Ortiz A.F.
Valle-Reconco J.A.
Bonilla-Aldana D.K.
Paniz-Mondolfi A.E.
Rodriguez-Morales A.J.
cris.boxmetadata.label.publisher
MDPI AG
cris.boxmetadata.label.abstract
Background: Mucormycosis is a life-threatening invasive fungal infection most commonly observed in immunocompromised patients. Throughout the COVID-19 pandemic, a growing number of Mucorales associated infections, now termed COVID-19 associated mucormycosis (CAM), have been reported. Despite an increase in fatality reports, no cases of rhino-orbital CAM complicated with gangrenous bone necrosis have been described in the literature to date. Case: A 56-year-old male with a recent COVID-19 diagnosis developed rhino-orbital mucormycosis after 22 days of treatment with dexamethasone. Cultures and histopathological assessment of tissue biopsy confirmed the diagnosis. The patient survived after treatment with amphotericin B. Conclusions: Mucormycosis is an invasive fungal infection affecting mostly immunocompromised patients. Along with the COVID-19 pandemic, the inappropriate use of steroids, in addition to concurrent risk factors, such as diabetes, has led to an increase in the occurrence of these devastating mycoses, leading to the development of severe presentations and complications, as observed in many cases. Early diagnosis and prompt treatment are crucial in order to avoid dissemination and fatal outcomes.
cris.boxmetadata.label.volume
9
cris.boxmetadata.label.issue
8
cris.boxmetadata.label.language
English
cris.boxmetadata.label.ocdeknowledgeArea
Epidemiología
Enfermedades infecciosas
cris.boxmetadata.label.subjects
cris.boxmetadata.label.doi
cris.boxmetadata.label.scopusidentifier
2-s2.0-85111713144
cris.boxmetadata.label.source
Vaccines
cris.boxmetadata.label.containerissn
2076393X
cris.boxmetadata.label.sponsor
The Facultad de Ciencias Médicas (FCM) (2-03-01-01), National Autonomous University of Honduras, Tegucigalpa, MDC, Honduras, supported the publication fees of this article. L.I.Z.
peru-layout.shadow-copies
Directorio de Producción Científica
Scopus